HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
NA | cobimetinib | Cotellic | 20 mg | Chemotherapy | MAPK/MEK Inhibitor | BRAF | Yes | 2015 | In Use | |||
N/A | Avutometinib potassium and defactinib hydrochloride | AVMAPKI FAKZYNJA CO-PACK | 0.8mg and 200mg | Chemotherapy | MEK Inhibitor, Tyrosine Kinase Inhibitor | MEK1/2, ERK1/2, KRAS | Yes | 2025 | In Use | |||
NA | Binimetinib | Mektovi | 15mg | Chemotherapy | MEK Inhibitor | MEK 1/2 | Yes | 2018 | In Use | |||
NA | Trametinib | Mekinist | 0.5 mg | Chemotherapy | MEK Inhibitor | BRAF | Yes | 2013 | In Use | |||
NA | Trametinib | Mekinist | 2 mg | Chemotherapy | MEK Inhibitor | BRAF | Yes | 2013 | In Use | |||
NA | Selumetinib | Koselugo | 10mg, 25mg | Chemotherapy | MEK Inhibitor | MEK 1/2 | Yes | 2020 | In Use | |||
J2783 | Rasburicase | Elitek, Fasturtec | 0.5 mg | Ancillary Therapy | Metabolic Agent | Enzyme | No | 2002 | Jan 1, 2004 | In Use | ||
J9266 | Pegaspargase | Oncaspar | unspecified | Chemotherapy | Miscellaneous Agent | Enzyme | No | 1994 | Jan 1, 1996 | In Use | ||
J9118 | Calaspargase pegol-mknl | Asparlas | 10 units | Chemotherapy | Miscellaneous Agent | Enzyme | No | 2018 | Oct 1, 2019 | In Use | ||
C9012 | Arsenic Trioxide | Trisenox | unspecified | Chemotherapy | Miscellaneous Agent | PML/RARa | No | 2000 | Jan 1, 2001 | Dec 31, 2001 | No Longer Used | |
J9019 | Asparaginase | Erwinaze | 10, 000 units (I.U.) | Chemotherapy | Miscellaneous Agent | Enzyme | No | 2011 | Jan 1, 2013 | In Use | ||
C9289 | Asparaginase | Erwinaze | 1,000 units (I.U.) | Chemotherapy | Miscellaneous Agent | Enzyme | No | 2011 | Apr 4, 2012 | Dec 31, 2014 | No Longer Used | |
Maribavir | Livtencity | 200mg | Ancillary Therapy | Miscellaneous Agent | CMV Antiviral | Yes | 2021 | In Use | ||||
J9017 | Arsenic Trioxide | Trisenox | 1 mg | Chemotherapy | Miscellaneous Agent | PML/RARa | No | 2000 | Jan 1, 2002 | In Use | ||
BA | Belzutifan | Welireg | 40mg | Chemotherapy | Miscellaneous Agent | HIF-2 alpha | Yes | 2021 | In Use | |||
S0176 | Hydroxyurea | Hydrea | 500 mg | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Yes | 1967 | Jan 1, 2002 | In Use | ||
NA | Pilocarpine Hydrochloride | Pilocarpine | 5mg, 10mg | Ancillary Therapy | Miscellaneous Agent | Cholinergic Agent | Yes | 2020 | In Use | |||
J9020 | Asparaginase | Erwinaze | 10, 000 units (I.U.) | Chemotherapy | Miscellaneous Agent | Enzyme | No | 1994 | Jan 1, 1984 | In Use | ||
J9021 | Asparaginase Erwinia Chrysanthemi (recombinant)-rywn | Rylaze | 0.1mg | Chemotherapy | Miscellaneous Agent | Enzyme | No | 2021 | Jan 26, 2022 | In Use | ||
Nirogacestat | Ogsiveo | 50mg, 100mg, 150mg | Ancillary Therapy | Miscellaneous Agent | Ɣ Secretase Inhibitor | Yes | 2023 | In Use | ||||
NA | Mitotane | Lysodren | unspecified | Chemotherapy | Miscellaneous Agent | Adrenal Suppressant | Yes | 1970 | In Use | |||
J9353 | Margetuximab-cmkb | Margenza | 5mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2021 | Jul 23, 2021 | In Use | ||
J9061 | Amivantamab | Rybrevant | 2mg | Immunotherapy | Monoclonal Antibody | EGFR, MET | No | 2021 | Jan 26, 2022 | In Use | ||
J9321 | Epcoritamab-bysp | Epkinly | 0.16mg | Immunotherapy | Monoclonal Antibody | CD20, CD3 | No | 2023 | Dec 7, 2023 | In Use | ||
J9350 | Mosunetuzumab-axgb | Lunsumio | 1mg | Immunotherapy | Monoclonal Antibody | CD20, CD3 | No | 2022 | Jul 11, 2023 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.